SBIR-STTR Award

The PROTEOMETER; A Continuous Upstream Process Monitoring Engine PHS 398 SPECIFIC RESEARCH PLAN I. . The global market for therapeutic monoclonal antibodies (T-mAbs) was $105 billion in 2018; twelve times the size of the clinical diagnostics market. Beyond their economic impact, mAbs have become a major force in medicine. This proposal addresses the fact that mAb proteoform variants of diminished activity and immunogenicity can be generated, but not monitored during production. The FDA has stressed the need to detect and remediated this problem since 2004 without success1. Proteoform specific analytics are not available for continuous monitoring of proteoforms in a fermentor. Novilytic is proposing herein a new analytical engine for continuous upstream process (CUSP) monitoring. The CUSP Proteometer being developed will have two analytical sectors working in parallel to extract samples from a fermentor, resolve mAb proteoforms, quantify them every 15- 30 min, and assess aberrant mAb proteoform production. Deviation in proteoform ratio will be sensed by the Proteometer, signaling of a potential aberrant will trigger in-depth bottom-up analyses. Aberrant proteoform suspects will be trypsin digested at 70 oC in an immobilized enzyme reactor, the effluent split by affinity selection into glycopeptide and non-glycopeptide fractions, and the fractions examined in PTM specific ways. PTM bearing peptide variants will be quantified and identified with multiple columns. More than 300 unattended analyses will be run during a two week mAb production campaign. The CUSP Proteometer data management system will blockchain code mAb structural and environmental data in relational source, time, protocol, and equipment performance blocks; enabling federal regulatory agencies to establish data authenticity, mAb quality throughout manufacturing, and potential aberrants. Having rapidly confirmed the safety and quality of a mAb lot it can be released by the FDA in “real-time”. Additionally, these digital histories can be built into a library and used to identify and remediate process weaknesses, enhance process analytics, and improve manufacturing as mandated by the FDA.

Public Health Relevance Statement:
PROJECT NARRATIVE As the production and market for high quality therapeutic monoclonal antibodies (mAbs) grows there is an expanding need for continuous upstream process (CUSP) monitoring. A concern with therapeutic mAbs is that aberrant proteoforms can arise during fermentation that will negatively impact patient health. They must not reach patients. The CUSP Proteometer described in this proposal will facilitate mAb manufacturing by continuously monitoring and alerting the manufacturing team to the production of aberrant mAbs. Beyond enabling immediate remediation, the Proteometer will collect and provide an encrypted tamper-proof history of manufacturing production runs for presentation to federal regulatory agencies. The value conveyed to manufacturers, regulatory agencies, and society is in assuring mAb product quality, reduction of manufacturing failures, reduced time-to-release following completion of a production run, and shorter time-to-market with new antibodies; all of which would add approximately 0.02% to mAb cost.

Project Terms:
Address; Affinity; Antibodies; Biological Assay; Biological Products; blockchain; Cells; Chromatography; clinical diagnostics; Code; Collaborations; Communication; Computer software; cost; Data; Data Management Resources; Development; digital; economic impact; encryption; enzyme reactor; Equipment; Failure; Fermentation; Glycopeptides; glycosylation; Goals; Health; High Pressure Liquid Chromatography; Hour; Immobilized Enzymes; immunogenicity; improved; Industry; Island; Libraries; Manufacturer Name; Medicine; Monitor; Monoclonal Antibodies; monoclonal antibody production; Operating System; Patients; Peptides; Performance; Phase; Process; Production; protein aggregation; Proteins; Protocols documentation; Recording of previous events; remediation; Research; research and development; Running; Safety; Sampling; Signal Transduction; Societies; software development; Source; Stress; Structure; System; Testing; Therapeutic Monoclonal Antibodies; Thinness; Time; Trypsin; Validation; Variant

The PROTEOMETER; A Continuous Upstream Process Monitoring EnginePHS 398 SPECIFIC RESEARCH PLANI. . The global market for therapeutic monoclonal antibodies (T-mAbs) was $105 billion in2018; twelve times the size of the clinical diagnostics market. Beyond their economic impact,mAbs have become a major force in medicine. This proposal addresses the fact that mAbproteoform variants of diminished activity and immunogenicity can be generated, but notmonitored during production. The FDA has stressed the need to detect and remediated thisproblem since 2004 without success1. Proteoform specific analytics are not available forcontinuous monitoring of proteoforms in a fermentor. Novilytic is proposing herein a newanalytical engine for continuous upstream process (CUSP) monitoring. The CUSP Proteometer being developed will have two analytical sectors working inparallel to extract samples from a fermentor, resolve mAb proteoforms, quantify them every 15-30 min, and assess aberrant mAb proteoform production. Deviation in proteoform ratio will besensed by the Proteometer, signaling of a potential aberrant will trigger in-depth bottom-upanalyses. Aberrant proteoform suspects will be trypsin digested at 70 oC in an immobilizedenzyme reactor, the effluent split by affinity selection into glycopeptide and non-glycopeptidefractions, and the fractions examined in PTM specific ways. PTM bearing peptide variants willbe quantified and identified with multiple columns. More than 300 unattended analyses will berun during a two week mAb production campaign. The CUSP Proteometer data management system will blockchain code mAb structuraland environmental data in relational source, time, protocol, and equipment performance blocks;enabling federal regulatory agencies to establish data authenticity, mAb quality throughoutmanufacturing, and potential aberrants. Having rapidly confirmed the safety and quality of amAb lot it can be released by the FDA in "real-time". Additionally, these digital histories can bebuilt into a library and used to identify and remediate process weaknesses, enhance processanalytics, and improve manufacturing as mandated by the FDA.

Public Health Relevance Statement:
PROJECT NARRATIVE As the production and market for high quality therapeutic monoclonal antibodies (mAbs) grows there is an expanding need for continuous upstream process (CUSP) monitoring. A concern with therapeutic mAbs is that aberrant proteoforms can arise during fermentation that will negatively impact patient health. They must not reach patients. The CUSP Proteometer described in this proposal will facilitate mAb manufacturing by continuously monitoring and alerting the manufacturing team to the production of aberrant mAbs. Beyond enabling immediate remediation, the Proteometer will collect and provide an encrypted tamper-proof history of manufacturing production runs for presentation to federal regulatory agencies. The value conveyed to manufacturers, regulatory agencies, and society is in assuring mAb product quality, reduction of manufacturing failures, reduced time-to-release following completion of a production run, and shorter time-to-market with new antibodies; all of which would add approximately 0.02% to mAb cost.

Project Terms: